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Abstract
Objectives: Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/r) provides an alternative treatment
option for HIV-1 infection that spares nucleoside analogs (NRTI) for future use and decreased toxicity. We hypothesized that
the level of immune activation (IA) and recovery of lymphocyte populations could influence virologic outcomes after
regimen simplification.
Methods: Thirty-four participants with virologic suppression $48 weeks on antiretroviral therapy (2 NRTI plus protease
inhibitor) were switched to ATV/r alone in the context of the ACTG 5201 clinical trial. Flow cytometric analyses were
performed on PBMC isolated from 25 patients with available samples, of which 24 had lymphocyte recovery sufficient for
this study. Assessments included enumeration of T-cells (CD4/CD8), natural killer (NK) (CD3+CD56+CD16+) cells and cell-
associated markers (HLA-DR, CD’s 38/69/94/95/158/279).
Results: Eight of the 24 patients had at least one plasma HIV-1 RNA level (VL).50 copies/mL during the study. NK cell levels
below the group median of 7.1% at study entry were associated with development of VL .50 copies/mL following
simplification by regression and survival analyses (p = 0.043 and 0.023), with an odds ratio of 10.3 (95% CI: 1.92–55.3).
Simplification was associated with transient increases in naı¨ve and CD25+ CD4+ T-cells, and had no impact on IA levels.
Conclusions: Lower NK cell levels prior to regimen simplification were predictive of virologic rebound after discontinuation
of nucleoside analogs. Regimen simplification did not have a sustained impact on markers of IA or T lymphocyte
populations in 48 weeks of clinical monitoring.
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Introduction
Trials of antiretroviral treatment (ART) simplification to
ritonavir-boosted protease inhibitors (PI) alone have shown mixed
success, with some trials mirroring the outcome of standard triple
therapy and others failing to show equivalence.[1,2] The criteria
for selection of patients for treatment simplification trials have
varied and include baseline CD4 T-cell counts, duration of prior
suppressive antiretroviral therapy and use of specific antiretroviral
agents, making it difficult to compare studies in order to identify
predictors of virologic outcome. Prior analyses have identified
duration of suppressive ART, low hemoglobin and poor adher-
ence as the major predictors of virologic rebound after treatment
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simplification.[3] However, these factors were not identified in all
trials, suggesting that there are other important determinants of
virologic outcomes.[1,2,4–6]
We assessed the immunologic determinants of sustained
virologic suppression in the AIDS Clinical Trials Group (ACTG)
protocol A5201. This was a prospective, open-label, single-arm
pilot trial of simplified maintenance therapy with atazanavir-
ritonavir (ATV/r) alone after prolonged virologic suppres-
sion.[7,8] At week 48, the Kaplan-Meier estimate of the
probability of virologic success was 88%.[8] Poor adherence was
only documented in 2 patients in the trial and undetectable
atazanavir levels were seen in some of the virologic failures in the
A5201 study; however, drug levels did not correlate with treatment
outcomes. [8] Studies of regimen simplification assume equal
recovery of T and natural killer (NK) cells after the CD4+ T-cell
counts have increased following antiretroviral therapy and levels of
HIV-1 RNA have been suppressed for a predetermined time
period. The A5201 study used an entry criterion of $250 CD4+ T
cells/mm3 to minimize risk of insufficient immune recovery prior
to maintenance treatment simplification, similar to other mainte-
nance simplification studies.[5,8–19] We hypothesized that the
level of immune activation and recovery of lymphocyte popula-
tions influence virologic outcomes for patients undergoing
induction-maintenance strategies. Indeed, virologic failure of
lopinavir/ritonavir (LPV/r) monotherapy was associated with
low nadir CD4+ T cell counts and suboptimal medication
adherence.[3] In a Swiss study, low nadir CD4+ T cell counts
were also associated with virologic failure, but in patients that had
only been suppressed for 3 months prior to treatment simplifica-
tion to LPV/r alone.[20] Additionally, trials of treatment
simplification have noted increased number of events of HIV-1
viremia above 50 copies/mL as compared to continued combi-
nation therapy, which may lead to an increase risk of virologic
failure and emergence of antiretroviral resistance.[23,24]
Our study therefore assessed the immune profile of patients
before regimen simplification, the impact of regimen simplification
on the T and NK cell populations and immune activation, and
whether these immunologic parameters correlated with levels of
residual viremia, measured by single copy assay, and detectable
viremia above 50 copies/mL.
Materials and Methods
Study population
The Institutional Review Boards of all the participating and
enrolling institutions listed in the acknowledgements approved the
A5201 study and each participant provided written informed
consent, these include: the University of Colorado Health Sciences
Center, Duke University, Stanford University, the University of
Nebraska Medical Center, Weill-Cornell Medical College, the
University of Pittsburgh, the University of Cincinnati, the
University of Hawaii–Manoa, the University of Iowa, the
University of North Carolina–Chapel Hill, the University of
Texas–Southwestern Medical Center, and the University of
Puerto Rico. Thirty-four participants underwent regimen simpli-
fication to ATV/r during the A5201 study. Participants included
in the study were receiving a protease inhibitor plus at least 2
NRTIs with plasma HIV-1 RNA suppression below 50 copies/
mL for at least 48 weeks immediately prior to study entry.[7] Four
participants experienced virologic failure by protocol definition
(defined as 2 consecutive plasma HIV-1 RNA levels $ 200 cop-
ies/mL) at weeks 12, 14, 20 and 28 after simplification. None of
these virologic failures developed PI resistance either by standard
genotyping or by single genome sequencing.[8] The virologic
failures were restarted on triple combination therapy and
remained on study until week 54. Of the 34 patients, 25
participants had available cryopreserved PBMC samples for flow
cytometry testing, which were collected at entry, and weeks 6, 18,
30 and 54. The 25 participants with available PBMCs did not
differ in age, race, nadir or baseline CD4 T cell count, and had
been virologically suppressed on average for the same duration as
the full study cohort (data not shown). At each time point, 206106
peripheral blood mononuclear cells (PBMC) were obtained and
stored at 2140uC. Of the 25 patients with available PBMC
samples, one was excluded from the analyses due to poor sample
quality (,10% viable PBMC from expected). Most of the PBMC
samples were collected at the same timepoints as the HIV-1 viral
load samples. All virologic failures as defined in the A5201 clinical
trial had available PBMCs and underwent flow cytometry
analyses. Clinical trial data including virologic outcomes, CD4
nadir and HIV-1 RNA levels were included in our analyses to
assess for potential impact on outcomes or in immune parameters.
In all participants, HIV-1 RNA levels were measured with the
Roche Amplicor Cobas v1.5 assay. To assess the impact of
treatment simplification on HIV-1 residual viremia in patients
with long standing HIV-1 suppression, the single copy assay
(SCA), having a limit of detection of 1.1 copies/mL as reported by
Palmer et al, was used in a subset of 13 participants, which
included all 4 participants with study defined virologic failure and
9 participants who had been previously amplified efficiently by
SCA in a prior study.[21,22] In this analysis, we will examine the
correlation of persistent HIV-1 residual viremia with immune
activation and cell population parameters.
Prior studies of PI monotherapy/simplification using lopinavir/
ritonavir have shown an increased prevalence of detectable HIV-1
RNA above 50 copies/mL; persistently detectable HIV-1 RNA
levels may potentially lead to virologic failure and emergence of
HIV resistance.[23,24] Therefore, we have used as criteria for
Figure 1. Baseline NK Cell percentages by HIV-1 RNA Outcome
following Regimen Simplification. Figure 1 compares the baseline
NK cell levels, defined by CD3-CD56+CD16+ cells, and virologic
outcome (HIV-1 RNA below or above 50 copies/mL, throughout the
study). The circles represent each study participant with either
sustained HIV-1 RNA suppression during the trial and those participants
who developed detectable viremia following treatment simplification.
The difference in the median NK cell levels between the groups with
detectable and suppressed viremia was statistically significant with a p-
value of 0.002. The median level is noted by the line in the scatterplot
for each group.
doi:10.1371/journal.pone.0095524.g001
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detectable HIV-1 RNA any value above 50 copies/mL, which is
different from the protocol defined virologic failure of confirmed
HIV-1 RNA levels above 200 copies/mL. Eight of the 24
participants tested by flow cytometry had at least one timepoint
with HIV-1 RNA.50 copies/mL during the trial, 3 with single, 2
with two consecutive and 3 with multiple detectable timepoints.
Seventeen participants had no HIV-1 RNA .50 copies/mL
during the trial. We compared immune parameters between the
participants with undetectable versus detectable HIV-1 RNA
viremia levels during the study.
Flow cytometric analyses
PBMC samples collected as part of the A5201 protocol at entry,
weeks 6, 18, 30 and 54 were used for the analyses. We expanded
the flow cytometry testing to include both T cell and NK cell
populations, as the latter is associated with early viremic control
and may contribute to the control of HIV-1 viremia in patients on
ART. The impact of the NK cell population on HIV-1 residual
viremia has not been previously evaluated. Cryopreserved PBMC
samples were thawed and cell viability was determined using a Vi-
CELL analyzer (Beckman Coulter, California) with a target of $
75% viability for each sample to be used for testing. For each
timepoint, 1.56106 cells were incubated in FACS buffer contain-
ing 2%BSA and 0.1% NaN3 along with appropriate combinations
of antibodies for 30 minutes following manufacturer’s recommen-
dations. The cells were then washed and resuspended in FACS
buffer. Flow cytometry data was immediately acquired by using
the LSR II flow cytometer (BD Biosciences), in accordance to the
manufacturer’s instructions. The antibodies used were purchased
from BD Biosciences (CD3-PB, anti-CD4-AF700, anti-CD45RO-
PE, anti-CD27-FITC, anti-CD69-PC-7, anti-CCR7-APC-AF700,
anti-CD38-PERCY5,5, anti-HLADR-APC-H7, anti-CD25-APC,
anti-CD95-FITC, anti-PD1-PE, and anti-CD69-PC7, anti-CD16-
PERCY5,5, anti-CD158a-FITC, anti-CD158b-PE, anti-CD94-
APC, and anti-CD69-PC7), Beckman-Coulter (anti-CD8-ECD),
eBioscience (anti-CCR7-APC-AF700) and BioLegend (anti-CD56-
AF700). Additional negative controls were included for each
sample during staining and acquisition steps. The parent cells were
the CD3+ T cell lymphocytes for our analyses and all other T and
NK cell percentages are based from this parent population. A gate
was set on the population of singlet events as determined by the
linear relationship between forward scatter height and area. This
was followed by a gate on the live population of lymphocytes based
on forward and side scatter light properties. The CD56 and CD3
parameters were plotted, and a gate was set on the NK cells based
on their classical definition of being CD56+/CD3- lymphocytes.
All flow cytometry gating and data were reviewed by both flow
cytometry technicians (two) and by the principal investigator to
confirm the validity of the samples, the gating strategy and the
final numbers, prior to inclusion into the final data set.
Statistics
All statistical analyses were performed using SPSS statistics 20
(IBM). Sample size was limited to patients participating in the
A5201 single arm study with available PBMC samples for
analyses. We used both parametric analyses including means test,
t-test, and non-parametric analyses including median test, the
Mann-Whitney-U, mixed model analyses, and Cox multivariate
regression analysis and cumulative survival analyses. Both
parametric and non-parametric test were used as appropriate.
Univariate analyses were used to examine potential predictors of
sustained virologic suppression with p-values # 0.1 which were
subsequently analyzed using both forward and backward multi-
variate regression analysis. Multivariate analyses was used to
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determine if any of the factors were true predictors of virologic
outcome and to eliminate any potential bias or confounding of
multiple comparisons/repeated testing producing a false positive
finding.[25] We reported the highest significant p-value for the
significant variables when examining both the multivariate
forward and backward regressions analyses. Statistical significance
was defined as P-values ,0.05, using a 2-tailed test for
multivariate analyses.
Results
Baseline immunologic parameters
Participants entering the study had a median CD4+ T cell count
of 616 (range: 443–756) cells/mm3. We compared the baseline T
and NK cell parameters between participants maintaining HIV-1
RNA suppression and those who did not (HIV-1 RNA .
50 copies/mL). At baseline, the CD4+ and CD8+ T cell
populations were similar for naı¨ve, central memory, effector
memory and CD25+ T cells between participants who maintained
suppression of HIV-1 RNA and those with detectable HIV-1 RNA
(all p-values were non-significant, Table 1). Nadir CD4 cell counts
did not correlate with virologic outcomes of detectable HIV-1
RNA above 50 copies/mL or with the assessed immune
parameters in multivariable analyses. However, the percentage
of CD32 cells that expressed CD56+ was significantly higher in
participants with undetectable viremia versus those with detectable
levels with a mean of 30.6% versus 13.6% (p = 0.03), and for co-
expression of CD56+CD16+ with mean value of 11.5% versus
3.2% (p,0.01). T cells expressing NK cell associated marker
CD56+ cell levels were also higher in participants with sustained
viral load (VL) suppression as compared to participants with
detectable VL, with median values of 7.2% versus 4.3% (p,0.01)
(Table 1, Figure 1). NK cell baseline differences were statistically
significant in both univariate and multivariate analyses including
Cox regression (Table 2). Higher NK cell population levels
correlated in our analyses with sustained HIV suppression
following treatment simplification.
Significant differences in T cell immune activation at baseline
were seen between the two groups. CD4+CD38+HLADR+,
CD8+CD69+, and CD32CD56+CD69+ percentages were higher
in the participants whose HIV-1 RNA levels remained suppressed
below 50 copies/mL during the study. In comparison of
participants with undetectable versus detectable viremia, the
median percentages for CD4+HLADR were 13.6% vs. 4.2%
(p = 0.01), CD4+CD69+ were 12.2% versus 6.3% (p = 0.02),
Table 2. Univariate and Multivariate Regression Analysis of Baseline T and NK Cell Populations and Immune Activation Markers
and the Risk of Detectable Plasma HIV-1 RNA.
Cox Regression Analysis
Cell Markers Univariate (p-value) Univariate OR (95% CI) Multivariate (p-value) Final OR (95% CI)
CD4+ CD69+ 0.071 13.2 (1.24–140.69) NS
CD4+ DR+ 0.093 4.2 (0.60–28.62) NS
CD4+ CD38+ DR+ 0.039 13.2 (1.24–140.69) NS
CD8+ CD69+ 0.033 4.2 (0.60–28.62) NS
CD8+ DR+ 0.045 13.2 (1.24–140.69) NS
CD8+ CD279+ 0.1 0.13 (0.01–1.34) NS
CD3+ CD56+ 0.012 13.2 (1.24–140.69) NS
CD32 CD56+ 0.033 13.2 (1.24–140.69) NS
CD32 CD56+ CD16+ 0.007 13.2 (1.24–140.69) 0.043 10.3 (1.92–55.3)
CD32 CD56+ CD69+ 0.053 4.2 (0.60–28.62) 0.055
CD32 CD56+ CD158a+ 0.093 1.71 (0.29–10.30) NS
Cox regression analyses included all variables with p-values #0.1 in the univariate analyses, and age, race and CD4 nadir prior to starting ART. Odds ratio above 1.0 are
associated with increased risk of virologic failure.
doi:10.1371/journal.pone.0095524.t002
Figure 2. Proportions with HIV-1 RNA , 50 copies/ml after
regimen simplification by baseline NK cell levels. Figure 2 shows
a Kaplan-Meier plot for the survival with HIV-1 RNA level above
50 copies/mL during the A5201 study based on the participant’s NK cell
level at study entry. The p-value is 0.023 by Kaplan-Meier analyses for
the difference at 54 weeks between the groups above and below the
median NK cell level.
doi:10.1371/journal.pone.0095524.g002
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CD4+CD38+HLADR+ were 3.6% versus 1.20% (p = 0.07),
CD8+HLADR+ were 16.8% versus 6.1% (p,0.01), CD8+CD69+
were 8.4% versus 3.7% (p = 0.03) and for CD56+CD69+ were
27.0% versus 15.9% (p = 0.04) (Table 1). The lower T cell immune
markers may represent early migration of activated T cells from
peripheral circulation to the tissues where active HIV replication is
ongoing in participants with detectable viremia.
Association of baseline immunologic status with
virological outcome
Cox univariate regression analyses of baseline immunologic
parameters as continuous variables were performed to assess for
any associations with the development of detectable HIV-1 RNA
levels above 50 copies/mL. Only 9 of the T or NK cell
populations or immune activation parameters analyzed had a p-
value of #0.1 in univariate regression, including CD4+CD69+,
CD4+CD38+HLA-DR+, CD8+HLA-DR+, CD8+CD69+,
CD8+CD279+, CD3+CD56+, CD32CD56+, CD32CD56+CD16+,
CD32CD56+CD69+ and CD32CD56+CD158a+. These immu-
nologic variables were included in a multivariable regression
analysis with forward and backward regression. We also included
participant demographic characteristics, including age and race,
and nadir CD4+ T cell count prior to start of antiretroviral
treatment. Only one parameter-population remained in the
model, CD32CD56+CD16+, with a p-value of 0.043 in forward
regression and 0.034 in backwards regression analyses. NK cells
expressing the CD69+ cell-associated marker of early activation
did not remain in the model but the p-value neared statistical
significance at 0.055 (Table 2). Cumulative survival analyses of the
impact of NK cells levels, as a dichotomous variable, determined
that participants with NK cell levels above the median of 7.1%
had reduced risk of developing detectable HIV-1 viremia above
50 copies/mL as compared to those with NK cell levels below the
median (p = 0.023) (Figure 2). The odds ratio of detectable HIV-1
RNA viremia in participants with low NK cell levels was 10.3
(95% CI: 1.92 to 55.3). Independent of baseline levels of immune
activation and other T cell populations, the baseline NK cell level
was the only predictive marker of detectable HIV-1 viremia in
multivariate regression following treatment simplification. Inter-
estingly, CD8+CD38+HLA-DR+ levels were statistically signifi-
cantly different at week 30 of the study in participants with and
without detectable viremia (p = 0.034) but the difference was not
present by week 54 (p = 0.67).
Correlation of T and NK cell populations and Immune
Activation (IA) Markers with HIV-1 RNA levels
Levels of T and NK cell populations and immune activation
markers were analyzed with HIV-1 RNA levels using both the
Single Copy Assay (SCA) and/or the Roche Amplicor v1.5 assay.
During the trial, blood samples with detectable HIV-1 RNA levels
below 50 copies/mL by SCA correlated with higher NK cells
expressing CD158b+ and CD94+ markers (r = 0.455 & 0.375, p-
values = 0.006 & 0.027, respectively). Other parameters were not
significantly correlated (data not shown).
When comparing samples with HIV-1 RNA levels 50–
99 copies/mL to those below 50 copies/mL by Roche Amplicor
v1.5, we determined that the higher viral load group had lower
median levels of CD4+CD45RO+CCR7+CD272 (0.1% vs. 0.4%,
p = 0.018), CD8+CD38+HLA-DR+ (1.3% vs. 1.8%, p = 0.013),
NK cells CD32CD56+CD16+ (4.6% vs. 11.5%, p = 0.036) and
CD56+CD94+ (38.3% vs. 59%, p = 0.005), in univariate analyses
(Figure 3). Other T and NK cell populations and IA markers were
not significantly different when compared at different HIV viral
load levels. In multivariate analyses, only NK cell levels remained
significant with detectable viremia (Table 2).
Impact of treatment simplification on T and NK cell
populations and IA
Comparisons of the T and NK cell populations and levels of IA
markers before and after treatment simplification revealed no
impact of treatment simplification on the immune parameters
examined. Participants with suppressed viremia during the study
tended to have an increase in the percentage of CD4+CD25+ cells
with treatment simplification (p = 0.08), but by study week 54 the
levels were similar to baseline (p = ns). The
CD4+CD45RO+CCR7+CD272 cell population also showed a
trend to increase following simplification in the participants with
Figure 3. Comparison of NK cells and T cell populations based on HIV-1 viremia below and above 50 copies/mL. Figure 3
demonstrates that the population percentage of CD3-CD56+CD16+ cells (panel 1) and CD4-CD45RO+CCR7+CD27- cells (panel 2) were decreased in
samples with HIV-1 RNA levels of 50–99 copies/mL as compared to samples obtained with HIV-1 RNA below 50 copies/mL with p-values of 0.036 and
0.018, respectively. The median level for each cell population is indicated by the line in the scatterplot for each group.
doi:10.1371/journal.pone.0095524.g003
NK Cell Populations & HIV Virologic Outcomes
PLOS ONE | www.plosone.org 6 May 2014 | Volume 9 | Issue 5 | e95524
suppressed viremia during the study but did not reach statistical
significance (p = 0.073). No statistically significant difference was
seen in immune activation levels following treatment simplification
in either outcome group. All other T and NK cell markers were
not statistically associated with treatment simplification (all p-
values .0.08 (data not shown).
Discussion
We examined the impact of baseline T and NK cell populations
and markers of immune activation on virologic outcomes following
regimen simplification to atazanavir/ritonavir alone. In addition,
the impact of regimen simplification on immunologic parameters
was investigated. Our study is the first to measure a possible
predictive value of baseline NK cell levels for virologic outcome.
Participants with NK cell levels below the median had 10 times
higher risk of developing HIV-1 RNA levels above 50 copies/mL
during the study. The difference in NK cell levels was seen in our
study group while patients were still on their original combination
antiretroviral therapy and before any intervention had occurred.
Increased incidence of detectable viremia above 50 copies/mL has
been reported in other trials of treatment simplification strategies
and has led to a concern for increased risk of virologic failure and
possible development of drug resistance mutations. [16,23,24,26]
Therefore, understanding the immunologic control of low level
viremia in participants undergoing treatment simplification and
selecting a stricter 50 copies/mL threshold was considered to be
more informative than using the study defined confirmed virologic
failure above 200 copies/mL for our analyses.
The NK cell levels and immune activation marker differences at
baseline demonstrate that despite prolonged HIV-1 RNA
suppression on antiretroviral therapy, participants had significant
differences in immunologic parameters at entry into the study.
Therefore the immune status of patients entering HIV clinical
trials as currently assessed by CD4+ T cell levels prior to study
entry does not provide a complete assessment of functional
immune status reconstitution, and duration of HIV-1 RNA
suppression may not be sufficient as an entry criterion for trials
of maintenance therapy. Other parameters that were associated
with detectable HIV-1 viremia at some point during the study
included markers of immune activation HLA-DR and CD38,
which could be indicators of undetected viral replication and/or
ongoing inflammation, and in turn impact treatment outcomes.
These markers reached statistical significance in univariate
analyses but did not remain in the model as significant factors in
multivariate analyses, possibly due to the limited sample size of our
study. Larger studies are needed to further evaluate if the cell
markers not retained in the regression models were affected by the
limited sample size and have a significant impact on ART
treatment responses.
Regimen simplification to atazanavir/ritonavir was not found to
be an independent predictor of changes in either T or NK cell
populations or on the levels of immune activation markers. We
observed initial gains in CD4+ naı¨ve and CD4+CD25+ T cells in
participants with virologic suppression during the trial but the
differences were not sustained after 48 weeks of simplification. In
the OK04 trial regimen simplification to LPV/r was associated
with a modest increase in CD4+ T cells at 48 weeks.[6] CD4+ T
cells increases were not detected in our study as previously
reported.[8]
HIV-1 residual viremia below 50 copies/mL and low level
viremia between 50–100 copies/mL were associated with distinct
changes in immune cell populations and activation markers. NK
cell CD158b+ and CD94+ surface cell markers tended to increase
with rising residual viremia by SCA. Once the HIV-1 RNA levels
were between 50–99 copies/mL, then CD4+ central memory T
cells, NK cells and markers of inflammation tended to decrease as
compared to samples from participants with suppressed HIV-1
RNA levels. These paradoxical decreases in markers of inflam-
mation could be related to migration of activated cells from the
circulation to the periphery as HIV-1 viral replication expands.
These findings may be relevant as we monitor patients with low
level detectable viremia or viral blips, as these could signify that
the low level increase in plasma HIV-1 RNA is due to actual
replication instead of assay variability.
Both the innate and adaptive immune systems have a role in the
host response against HIV-1 viral replication. Initial viremia
control in acute infection is achieved by cytotoxic activity of CD8+
T and NK cell responses.[27,28] NK cells are known to be
involved in both the early antiviral response to HIV-1 infection
and represent an important part of innate and possibly adaptive
immune response to control HIV-1 viral replication.[27–32]
Concomitant CD4+ and CD8+ T cell responses to Gag peptides
and NK cell responses to Env and Reg peptides have been
correlated with improved viremia control and higher CD4+ T cell
counts.[33] NK cell responses to HIV-1 peptides have been
demonstrated to persist even in absence of CD4+ and CD8+ T cell
responses.[33] NK cell population levels and the phenotypic
changes identified in our study suggest a more robust role of these
cells in functional and cytotoxic activities related to control of
HIV-1 replication in patients with detectable viremia below
50 copies/mL. Prior studies have shown that either changes in
NK cell phenotype or functionality can impact HIV-1 viral control
when assessed in long-term non-progressors and HIV-1 control-
lers.[34,35] Decreases in CD56bright subsets, NKp30 and NKp46
expression in NK cells have been associated with reduced
activation and cytotoxic activity with progressive HIV-1 infec-
tion.[36–39] NK cell exhaustion may also be associated with
decreased viremic control, as HIV controllers expressed normal
Siglec-7 levels as compared to HIV-1 progressors.[40] Similarly,
PBMCs obtained from of long term non-progressors show normal
to low expression of different inhibitory natural killer receptors
(iNKR) in CD3+CD8+ CTL cells and lack of inhibition of HIV-1
specific cytotoxic activity by iNKR in vitro suggesting that
normalized receptor expression may be needed for on-going
anti-HIV cytotoxic activity.[41] Virologic failure may be as
dependent on the host innate immune responses beyond just
CD4+ T cell recovery as it is on regimen potency.
The A5201 study was designed as a single arm study, which
limits our ability to compare our results to control participants not
undergoing treatment simplification. SCA HIV-1 viral load data
are also limited to 13 participants who were known to have
amplifiable HIV-1 gag sequences, limiting the depth of the
analyses below 50 copies/mL. Low level detectable HIV-1 viremia
above 50 copies/mL seen in this study may represent either new
full rounds of replications due to incomplete suppression or viral
shedding from previously infected cells. In the A5201 study, no PI
resistance mutations were detected by either standard or single
genome sequencing to support possible viral evolution and
therefore new rounds of replication. Poor medication adherence
will impact virologic rebound and was documented in at least two
A5201 study participants. However, most study participants
indicated good medication adherence during the trial and had
been suppressed for longer to 12 months prior to study entry.[8]
Atazanavir drug levels were evaluated in the original study but
were not correlated with virologic outcomes, except if no level was
detected (data not shown). Study medication adherence is unlikely
to have impacted baseline T and NK populations prior to study
NK Cell Populations & HIV Virologic Outcomes
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intervention, unless inconsistent medication adherence had been
unrecognized prior to study entry and had not resulted in virologic
rebound. Due to the original study sample size and sample
availability, our final sample size is relatively small and some of the
variables tested may not have reached statistical significance due to
a type B error. Larger studies will be needed to further assess our
study results and elucidate the impact of other immunologic
parameters on HIV-1 viremic control. The strength of our study,
however, lies in the depth and robustness of the immunologic flow
cytometric analyses which included T and NK cells, together with
correlation with clinical outcomes and HIV-1 RNA levels from
both single copy assay and standard viral load testing.
In summary, this study demonstrates that patients on suppres-
sive ART for similar timeframes have distinct immune cell
populations and levels of cellular activation, despite CD4+ T cell
counts on average above 600 cells/mm3, and even after adjusting
for nadir CD4+ T cell counts. Different levels of immune
reconstitution and activation may explain the differences in
treatment outcomes in trials of maintenance regimen simplifica-
tion, and could explain why some patients may not require triple
combination therapy to maintain HIV-1 suppression. Future trials
of maintenance therapy strategies should include more in-depth
immune assessments to further confirm these findings and better
understand the relationship between the NK cell populations and
other immune markers and treatment outcomes. Baseline assess-
ment of NK cell levels and immune activation markers could
provide information for early detection of patients at increased risk
of virologic failure.
Acknowledgments
We would like to thank the participants and investigators that contributed
to this study. ACTG 5201 team members (other than the coauthors) are as
follows: Ste´phannie Charles (data manager, Frontier Science & Technol-
ogy Research Foundation), Elaine Ferguson (pharmacist, DAIDS, NIAID,
NIH), Todd Stroberg (field representative, Cornell Clinical Trials Unit,
Cornell University), Lori Mong-Kryspin (laboratory technologist, Ohio
State University), Philip Anthony (National Community Advisory Board
representative, ACTG), and Courtney Ashton (laboratory coordinator,
Frontier Science & Technology Research). Dr. Susan Swindells partici-
pated as both the protocol chair for the original A5201 study team and as a
co-investigator in this project. Enrolling research sites were as follows: the
University of Colorado Health Sciences Center (Cathi Basler and John
Koeppe), Duke University (Charles Hicks and Robin May), Stanford
University (Debbie Slamowitz and Sylvia Stoudt), the University of
Nebraska Medical Center (Sharon Richard and Frances Van Meter),
Weill-Cornell Medical College (Glenn Sturge and Roy Gulick), the
University of Pittsburgh (Deborah McMahon and Nancy Mantz), the
University of Cincinnati (Linda Hinds and Peter Frame), the University of
Hawaii–Manoa (Debra Ogata-Arakaki and Scott Souza), the University of
Iowa (Jeffery Meier and Barbara Wiley), the University of North Carolina–
Chapel Hill (Joseph Eron and Susan Richard), the University of Texas–
Southwestern Medical Center (Philip Keiser and Chip Lohner), and the
University of Puerto Rico (Jorge Santana and Olga Me´ndez). Special
thanks to the clinical trial units at Duke University, Weill-Cornell Medical
College, the University of North Carolina–Chapel Hill, the University of
Colorado Health Science Center, and Sarah Palmer, PhD for their
valuable assistance with the single-copy-assay studies.
Author Contributions
Conceived and designed the experiments: JEM RBM SS TJW JWM CRR.
Performed the experiments: JEM RBM LB JMR MK AW. Analyzed the
data: JEM RBM LB JMR MK AW JWM CRR. Contributed reagents/
materials/analysis tools: JEM RBM LB JMR MK AW BB JWM CRR.
Wrote the paper: JEM RBM SS TJW LB JMR BB MK AW JWM CRR.
Regulatory and study development: BB.
References
1. McKinnon JE, Mellors JW, Swindells S (2009) Simplification strategies to reduce
antiretroviral drug exposure: progress and prospects. Antivir Ther 14: 1–12.
2. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA, et al.
(2009) HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic
review. AIDS 23: 279–291.
3. Pulido F, Perez-Valero I, Delgado R, Arranz A, Pasquau J, et al. (2009) Risk
factors for loss of virological suppression in patients receiving lopinavir/ritonavir
monotherapy for maintenance of HIV suppression. Antiviral Therapy 14: 195–
201.
4. Perez-Valero I, Arribas JR, Perez-Valero I, Arribas JR (2011) Protease inhibitor
monotherapy. Current Opinion in Infectious Diseases 24: 7–11.
5. Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, et al. (2010) The
MONET trial: darunavir/ritonavir with or without nucleoside analogues, for
patients with HIV RNA below 50 copies/ml. AIDS 24: 223–230.
6. Arribas JR, Delgado R, Arranz A, Munoz R, Portilla J, et al. (2009) Lopinavir-
ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for
maintenance therapy of HIV: 96-week analysis. Journal of Acquired Immune
Deficiency Syndromes: JAIDS 51: 147–152.
7. Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, et al. (2006)
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretro-
viral therapy after sustained virologic suppression. JAMA 296: 806–814.
8. Wilkin TJ, McKinnon JE, DiRienzo AG, Mollan K, Fletcher CV, et al. (2009)
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretro-
viral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 199:
866–871.
9. Wong AH, Williams K, Reddy S, Wilson D, Giddy J, et al. (2010) Alterations in
natural killer cell receptor profiles during HIV type 1 disease progression among
chronically infected South African adults. AIDS Res Hum Retroviruses 26: 459–
469.
10. Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, et al. (1998) A
randomized trial of three maintenance regimens given after three months of
induction therapy with zidovudine, lamivudine, and indinavir in previously
untreated HIV-1-infected patients. Trile`ge (Agence Nationale de Recherches sur
le SIDA 072) Study Team. New England Journal of Medicine 339: 1269–1276.
11. Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, et al. (1998)
Maintenance therapy after quadruple induction therapy in HIV-1 infected
individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
Lancet 352: 185–190.
12. Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, et al. (2001) The
ADAM study continued: maintenance therapy after 50 weeks of induction
therapy. AIDS 15: 129–131.
13. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, et al. (2003)
TRIZAL study: switching from successful HAART to Trizivir (abacavir-
lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and
adherence results. HIV Medicine 4: 79–86.
14. Gathe JC Jr, Yeh RF, Mayberry C, Nemecek J, Miguel B, et al. (2007) Single-
agent Therapy with Lopinavir/ritonavir Suppresses Plasma HIV-1 Viral
Replication in HIV-1 Naive Subjects: IMANI-2 48-Week Results; July 22–25.
15. Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, et al. (2005) Lopinavir/
ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-
week results of a randomized, controlled, open-label, proof-of-concept pilot
clinical trial (OK Study). Journal of Acquired Immune Deficiency Syndromes:
JAIDS 40: 280–287.
16. Pulido F, Arribas JR, Delgado R, Cabrero E, Gonza´lez-Garcı´a J, et al. (2008)
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides
for maintenance therapy of HIV. AIDS 22: F1–F9.
17. Cameron W, da Silva B, Arribas J, Myers R, Bellos N, et al. (2006) A two-year
randomized controlled clinical trial in antiretroviral-naı¨ve subjects using
lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment
compared to an efavirenz (EFV) 3-drug regimen (Study M03-613). 13-18
August; Toronto, Canada.
18. Kahlert C, Hupfer M, Wagels T, Bueche D, Fierz W, et al. (2004) Ritonavir
boosted indinavir treatment as a simplified maintenance ‘‘mono’’-therapy for
HIV infection. AIDS 18: 955–957.
19. Pulido F, Serrano O, Rivero A (2009) Atazanavir/ritonavir for maintenance of
virologic suppression:48 week primary analysis of the 96 week multicenter, open-
label, single-arm, pilot OREY Study. 12th EACS Conference; Cologne, 11–14
November. pp. Oral Abstract PS 4/6.
20. Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, et al. (2010)
Randomized controlled study demonstrating failure of LPV/r monotherapy in
HIV: the role of compartment and CD4-nadir. AIDS 24: 2347–2354.
21. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, et al. (2003) New
real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity
for human immunodeficiency virus type 1 RNA in plasma. Journal of Clinical
Microbiology 41: 4531–4536.
NK Cell Populations & HIV Virologic Outcomes
PLOS ONE | www.plosone.org 8 May 2014 | Volume 9 | Issue 5 | e95524
22. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-
level viremia persists for at least 7 years in patients on suppressive antiretroviral
therapy. Proceedings of the National Academy of Sciences of the United States
of America 105: 3879–3884.
23. Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, et al. (2009) Protease
inhibitor resistance analysis in the MONARK trial comparing first-line
lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and
lamivudine triple therapy. Antimicrobial Agents & Chemotherapy 53: 2934–
2939.
24. Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, et al. (2008) A
96-week comparison of lopinavir-ritonavir combination therapy followed by
lopinavir-ritonavir monotherapy versus efavirenz combination therapy. Journal
of Infectious Diseases 198: 234–240.
25. LaValley MP (2008) Logistic regression. Circulation 117: 2395–2399.
26. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, et al. (2012) Plasma
HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in
patients receiving highly active antiretroviral therapy. Clinical Infectious
Diseases 54: 724–732.
27. Berger CT, Alter G, Berger CT, Alter G (2011) Natural killer cells in
spontaneous control of HIV infection. Current Opinion in HIV & AIDS 6: 208–
213.
28. Alter G, Teigen N, Ahern R, Streeck H, Meier A, et al. (2007) Evolution of
innate and adaptive effector cell functions during acute HIV-1 infection. Journal
of Infectious Diseases 195: 1452–1460.
29. Alter G, Altfeld M (2009) NK cells in HIV-1 infection: evidence for their role in
the control of HIV-1 infection. Journal of Internal Medicine 265: 29–42.
30. Sun JC, Beilke JN, Lanier LL, Sun JC, Beilke JN, et al. (2009) Adaptive immune
features of natural killer cells. Nature 457: 557–561.
31. Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Papathanaso-
poulos MA, et al. (2009) Cutting Edge: Unusual NK cell responses to HIV-1
peptides are associated with protection against maternal-infant transmission of
HIV-1. Journal of Immunology 182: 5914–5918.
32. Chakrabarti LA, Simon V, Chakrabarti LA, Simon V (2010) Immune
mechanisms of HIV control. Current Opinion in Immunology 22: 488–496.
33. Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Papathanaso-
poulos MA, et al. (2010) Natural Killer Cells That Respond to Human
Immunodeficiency Virus Type 1 (HIV-1) Peptides Are Associated with Control
of HIV-1 Infection. Journal of Infectious Diseases 202: 1444–1453.
34. Vieillard V, Fausther-Bovendo H, Samri A, Debre P, and French Asymptoma-
tiques a Long Terme A-COSG, et al. (2010) Specific phenotypic and functional
features of natural killer cells from HIV-infected long-term nonprogressors and
HIV controllers. Journal of Acquired Immune Deficiency Syndromes: JAIDS
53: 564–573.
35. Johansson SE, Hejdeman B, Hinkula J, Johansson MH, Romagne F, et al. (2010)
NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-
infected autologous cells in viremic and controller HIV-infected patients.
Clinical Immunology 134: 158–168.
36. Bjorkstrom NK, Ljunggren HG, Sandberg JK, Bjorkstrom NK, Ljunggren H-G,
et al. (2010) CD56 negative NK cells: origin, function, and role in chronic viral
disease. Trends in Immunology 31: 401–406.
37. Barker E, Martinson J, Brooks C, Landay A, Deeks S, et al. (2007) Dysfunctional
natural killer cells, in vivo, are governed by HIV viremia regardless of whether
the infected individual is on antiretroviral therapy. AIDS 21: 2363–2365.
38. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, et al. (2003)
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on
inhibitory and activating receptors and their functional correlates.[Erratum
appears in Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6326]. Proceedings
of the National Academy of Sciences of the United States of America 100:
15011–15016.
39. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, et al. (2003) The impaired
NK cell cytolytic function in viremic HIV-1 infection is associated with a
reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30
and NKp44). European Journal of Immunology 33: 2410–2418.
40. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, et al. (2009) The
decreased expression of Siglec-7 represents an early marker of dysfunctional
natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood
114: 3822–3830.
41. Costa P, Rusconi S, Mavilio D, Fogli M, Murdaca G, et al. (2001) Differential
disappearance of inhibitory natural killer cell receptors during HAART and
possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. AIDS 15:
965–974.
NK Cell Populations & HIV Virologic Outcomes
PLOS ONE | www.plosone.org 9 May 2014 | Volume 9 | Issue 5 | e95524
